Alumis (NASDAQ:ALMS) Insider Sanam Pangali Sells 5,000 Shares of Stock

Alumis Inc. (NASDAQ:ALMS) insider Sanam Pangali sold 5,000 shares of the business’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $28.00, for a total value of $140,000.00. Following the transaction, the insider directly owned 11,111 shares of the company’s stock, valued at $311,108. The trade was a 31.03% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Alumis Price Performance

Shares of ALMS opened at $29.74 on Thursday. The firm’s 50 day simple moving average is $23.47 and its 200 day simple moving average is $23.31. The company has a market capitalization of $3.79 billion, a P/E ratio of -15.02 and a beta of -0.73. Alumis Inc. has a 1-year low of $3.24 and a 1-year high of $31.35.

Alumis (NASDAQ:ALMS) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). The company had revenue of $1.74 million during the quarter, compared to analysts’ expectations of $2.10 million. Alumis had a negative return on equity of 88.79% and a negative net margin of 2,825.70%. On average, equities analysts anticipate that Alumis Inc. will post -2.87 earnings per share for the current year.

Institutional Investors Weigh In On Alumis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Samsara Biocapital LLC boosted its holdings in shares of Alumis by 19.9% during the 4th quarter. Samsara Biocapital LLC now owns 5,756,984 shares of the company’s stock valued at $56,188,000 after buying an additional 955,614 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Alumis by 18.4% in the 3rd quarter. Vanguard Group Inc. now owns 4,029,615 shares of the company’s stock worth $16,078,000 after buying an additional 625,404 shares during the period. Cormorant Asset Management LP increased its stake in shares of Alumis by 69.3% in the 4th quarter. Cormorant Asset Management LP now owns 3,635,596 shares of the company’s stock worth $35,483,000 after acquiring an additional 1,488,200 shares in the last quarter. Octagon Capital Advisors LP increased its stake in shares of Alumis by 11.9% in the 1st quarter. Octagon Capital Advisors LP now owns 2,830,700 shares of the company’s stock worth $62,360,000 after acquiring an additional 300,000 shares in the last quarter. Finally, MPM Bioimpact LLC purchased a new position in Alumis during the 4th quarter valued at about $23,443,000.

Wall Street Analysts Forecast Growth

ALMS has been the subject of several research reports. Oppenheimer upped their target price on shares of Alumis from $50.00 to $55.00 and gave the stock an “outperform” rating in a research report on Monday, March 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Alumis in a research report on Tuesday. Citigroup reaffirmed a “buy” rating on shares of Alumis in a research note on Tuesday, May 19th. Chardan Capital upped their price objective on shares of Alumis from $38.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, May 19th. Finally, Guggenheim increased their price target on shares of Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Alumis presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.30.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.